MHE Week in Review - HIV

All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, clinic reached or kept viral suppression over a median of 100 weeks.

UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.

UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.

Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.

Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility.

Pooja Roy, M.D., of Houston Methodist Hospital, discusses how Precedex (dexmedetomidine), an ICU sedative, sometimes triggers noninfectious fever, sparking costly sepsis workups, and the need for a test could help clinicians identify the drug as a cause of fever in ICUs.

Pope Leo early-stage adenocarcinoma is a reminder that lung nodules often cause no symptoms and that people who never smoked can get lung cancer.

Young-onset lung cancer often strikes nonsmokers, and current screening based on smoking is not likely to find it, says Singhi, an assistant professor at UT MD Anderson Cancer Center in Houston. New risk-based screening, liquid biopsies, and breath tests aim earlier detection.